targeting selectivity for cox 2 reduces the risk of peptic ulceration and is the main feature of celecoxib rofecoxib and other members of this drug class after several cox 2 inhibiting drugs were approved for marketing data from clinical trials revealed that cox 2 inhibitors caused a significant increase in heart attacks and strokes with some drugs in the class having worse risks than others rofecoxib commonly known as vioxx was taken off the market in 2004 because of these concerns and celecoxib and traditional nsaids received boxed warnings on their labels many cox 2 specific inhibitors have been removed from the u s market as of december 2011 only celebrex generic name is celecoxib is still available for purchase in the united states some cox 2 inhibitors are used in a single dose to treat pain after surgery etoricoxib appears as good as if not better than other pain medications celecoxib appears to be about as useful as ibuprofen nsaids are often used in treatment of acute gout attacks cox 2 inhibitors appear to work as well as nonselective nsaids they have not been compared to other treatment options such as colchicine or glucocorticoids cox 2 appears to be